Robert F. Kennedy Jr.'s ascendance creates environment where vaccine development becomes harder
Kennedy's skepticism toward vaccines and defunding of mRNA research is making it significantly harder for new vaccines to be developed, scientists and investors say.
Objective Facts
Robert F. Kennedy Jr. has brought major changes in his time at the health department since becoming health secretary early last year, including winding down mRNA vaccine development, withdrawing funding for an international vaccine alliance and tightening access to COVID shots. Kennedy announced that 22 projects, totaling $500 million, to develop vaccines using mRNA technology will be halted. The effect on the biotech industry has been severe: in 2023, investors poured more than $500 million into mRNA vaccines, but last year that figure collapsed to $174 million—a 66% decline in a single year. The ascendance of vaccine critic Robert F. Kennedy Jr. as the top health official is creating an environment where promising vaccines are harder to develop, according to scientists and investors.
Left-Leaning Perspective
The Washington Post reported that Robert F. Kennedy Jr.'s skeptical approach to vaccines is making it hard to fund and develop new ones, according to scientists and investors. Peter Hotez of Baylor College of Medicine warned that under Kennedy's leadership, HHS is signaling that the federal government may no longer be a reliable driver of biomedical innovation. Rick Bright, who ran BARDA during the first Trump administration, called Kennedy's move "irresponsible" and said "We're taking our country from 2025 back to 1940, and we all know that's a recipe for disaster and failure". Left outlets emphasize lost scientific momentum and investor confidence as core harms.
Right-Leaning Perspective
Mainstream right-leaning outlets frame Kennedy's vaccine policies as damaging American scientific and economic competitiveness, even if some right-leaning commentators support vaccine skepticism. The Washington Examiner warns that Kennedy's work to discredit certain vaccines is at odds with Operation TrialBlazer's goal of promoting innovative medicines, and that at a critical moment for global scientific competition with China, the U.S. cannot afford to be stuck in the past, especially on mRNA technology. The same outlet notes that Kennedy's public skepticism has dwindled but he quietly continues work to discredit vaccine safety and benefits, behavior at odds with innovation goals. Right outlets emphasize competitive disadvantage and national security.
Deep Dive
Kennedy's ascension to HHS leadership created a measurable chilling effect on vaccine development investment and federal support. The $500 million cut to 22 mRNA vaccine projects in August 2025 was the most visible action, but the broader impact operates through regulatory uncertainty. When FDA officials under Kennedy's oversight reject or heavily scrutinize vaccine applications (as occurred with Moderna's flu vaccine), companies interpret that as signal that their pipeline faces political rather than scientific evaluation. This interpretation has quantifiable consequences: private mRNA vaccine investment collapsed from $500+ million in 2023 to $174 million in 2024—a 66% decline. Moderna's CEO explicitly stated the company would halt late-stage U.S. trials because returns cannot be guaranteed in a hostile regulatory environment. Smaller biotech firms and manufacturing ventures have reportedly shelved expansion plans. The development pipeline doesn't just slow; it exits—companies pursue trials and manufacturing elsewhere. This creates the specific mechanism by which Kennedy's policies make vaccine development harder: not by banning it, but by making the U.S. a less reliable jurisdiction for investment, regulatory approval, and manufacturing. What each side gets right and leaves out: The left correctly identifies that Kennedy's skepticism of mRNA vaccines, including his claims about safety unsupported by evidence, has created regulatory unpredictability that chills investment. They correctly note the competitive advantage China is gaining. What they understate is that some alternative vaccine platforms (like whole-virus vaccines) have genuine merit for certain applications, and legitimate scientific debate exists about mRNA's appropriate role in pandemic preparedness versus other technologies. The right correctly identifies that China is advancing mRNA development while U.S. investment retreats, framing this as a strategic loss. They also note that Kennedy may sincerely believe alternative platforms are safer, even if that belief contradicts scientific consensus. What they understate is the magnitude of evidence supporting mRNA vaccines' safety and efficacy, and the speed advantage of the technology that makes it uniquely suited to pandemic response. Both sides agree on one fact: Kennedy's policies are making it harder to develop new vaccines in the U.S. market, even as they disagree sharply on whether this is justified. What to watch: Whether Moderna and other companies follow through on threats to move manufacturing and trials overseas, effectively transferring U.S. competitive advantage in mRNA medicine to foreign jurisdictions. Whether Kennedy's resistance from different corners of government, including within the health department and White House, continues to block his most ambitious changes. Whether the 2026 midterm elections prompt Kennedy to retreat from the most visible anti-vaccine rhetoric while continuing to reshape FDA and HHS policy behind the scenes. Whether alternative vaccine platforms Kennedy favors actually advance development timelines and efficacy, or whether they're simply slower with no offsetting benefit.